Noelle K. Eder - 14 May 2024 Form 4 Insider Report for Cigna Group (CI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 May 2024, 17:22:42 UTC
Prior SEC filing
05 Mar 2024
Next SEC filing
07 Jan 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Matthew Arnold, attorney-in-fact

Key filing fact

Noelle K. Eder filed Form 4 for Cigna Group (CI) on 16 May 2024.

Key facts

  • This page summarizes Noelle K. Eder's Form 4 filing for Cigna Group (CI).
  • 5 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 16 May 2024, 17:22.

Change

  • Previous filing in this sequence was filed on 05 Mar 2024.
  • Current net transaction value: -$2,630,394.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CI transaction

Common Stock, $.01 Par Value

Options Exercise

Transaction value
$948,273
Shares
+5,533
Change %
+26%
Price
$171.38
Shares after
26,524
Date
14 May 2024
Ownership
Direct
Footnotes
F1
CI transaction

Common Stock, $.01 Par Value

Sale

Transaction value
$3,728,629
Shares
-10,700
Change %
-40%
Price
$348.47
Shares after
15,824
Date
14 May 2024
Ownership
Direct
Footnotes
F1
CI transaction

Common Stock, $.01 Par Value

Options Exercise

Transaction value
$149,962
Shares
+875
Change %
+5.5%
Price
$171.38
Shares after
16,699
Date
15 May 2024
Ownership
Direct
Footnotes
F1
CI holding

Common Stock, $.01 Par Value

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
176
Date
14 May 2024
Ownership
By 401(k)
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CI transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-5,533
Change %
-86%
Price
$0.000000
Shares after
875
Date
14 May 2024
Ownership
Direct
Underlying class
Common Stock, $.01 Par Value
Underlying amount
5,533
Exercise price
$171.38
Footnotes
F1, F3
CI transaction Derivative

Employee Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-875
Change %
-100%
Price
$0.000000*
Shares after
0
Date
15 May 2024
Ownership
Direct
Underlying class
Common Stock, $.01 Par Value
Underlying amount
875
Exercise price
$171.38
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 9, 2024.

Footnote F2

Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

Footnote F3

This option was granted on September 14, 2020. The option vested in two equal annual installments on the first and second anniversaries of the grant date.

SEC remarks

EVP, Global Chief Information Officer

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .